OGI

Organigram Holdings

OGI

Market cap $232M

Overview Fund Activity

1.73 USD

+0.02

1.17%

At close Updated Sep 16, 1:08 PM EDT

1 day

1.17%

5 days

6.79%

1 month

13.07%

3 months

20.98%

6 months

61.68%

Year to date

4.22%

1 year

-8.47%

5 years

-62.72%

10 years

-94.46%

About: Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.

Employees: 1,150

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,240% more call options, than puts

Call options by funds: $117K | Put options by funds: $5K

163% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 8

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

57% more capital invested

Capital invested by funds: $6.25M [Q1] → $9.81M (+$3.56M) [Q2]

17% more funds holding

Funds holding: 63 [Q1] → 74 (+11) [Q2]

0.57% more ownership

Funds ownership: 4.88% [Q1] → 5.46% (+0.57%) [Q2]

See Fund Rankings

Financial journalist opinion

Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), Canada's largest cannabis company by market share, today released "High Impact, Green Growth: The Economic Footprint of Canada's Cannabis Industry," a national report done in partnership with the Business Data Lab at the Canadian Chamber of Commerce. The report, which examined figures for 2024, underscores the legal cannabis sector's role as a major driver of jobs, economic growth, and innovation, highlighting why it sho.

Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024

Organigram: The Capital Efficient Market Leader Trading At A Discount

Organigram Global Inc. presents a unique value proposition through its disciplined approach of doubling down on the Canadian market and cautiously expanding its footprint globally. Margin headwinds witnessed in Q3 can be easily addressed through the increased harvesting capacity following optimizations and upgrades. Canadian LPs redirecting their cannabis to international markets allowed Organigram to become the market leader in terms of market share and widen its gap with its nearest competitor, Tilray.

Organigram: The Capital Efficient Market Leader Trading At A Discount

Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

Title: Organigram Global Inc. (NASDAQ:OGI ) Q3 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Beena G. Goldenberg - CEO & Director Greg Guyatt - Chief Financial Officer Max Schwartz - Director of Investor Relations Conference Call Participants Aaron Thomas Grey - Alliance Global Partners, Research Division Frederico Yokota Choucair Gomes - ATB Capital Markets Inc., Research Division Operator Good morning.

Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

Organigram Posts Wider Loss, Eyes Profitability In Near Term

Cannabis grower Organigram Holdings Inc. OGI reported third-quarter 2025 net sales of $51.14 million, approximately $70.8 million Canadian dollars (CAD), up 72% year-over-year, beating the consensus of $48.33 million.

Organigram Posts Wider Loss, Eyes Profitability In Near Term

Zacks Investment Research

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

OrganiGram (OGI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.02 per share a year ago.

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Organigram Reports Record Third Quarter Fiscal 2025 Results

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 (“Q3 Fiscal 2025” or “Q3”). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-.

Organigram Reports Record Third Quarter Fiscal 2025 Results

Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, plea.

Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today that its recently acquired beverage business, Collective Project, has launched an e-commerce platform in the U.S. marking a key milestone in the Company's strategic expansion into the rapidly evolving U.S. hemp-derived THC beverage market. The launch also includes a bold new portfolio of hemp-derived THC beverages designed to m.

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

Americans Should Buy Canadian Cannabis Companies

Canadian LPs offer compelling risk/reward versus U.S. cannabis stocks, with stronger balance sheets, tangible book value, and global opportunities due to federal legality. Despite recent rallies, Canadian LPs remain cheap on enterprise value to EBITDA, especially Village Farms, Organigram, and Tilray Brands, which I hold in my model portfolio. U.S. MSOs face significant risks from 280E tax liabilities and negative tangible equity, making Canadian LPs a safer bet for cannabis investors right now.

Americans Should Buy Canadian Cannabis Companies

MarijuanaStocks

June 2025 Watchlist: Best Canadian Cannabis Stocks for Growth

As of June 2025, the U.S. cannabis industry continues its rapid expansion. Projections estimate the market will reach approximately $45 billion in revenue this year. This growth is fueled by increasing consumer demand, introducing innovative products, and technological advancements in cultivation and production. Despite federal prohibition, 24 states have legalized adult-use cannabis, and 39 states have legalized medical cannabis. However, federal legalization efforts face challenges. In May 2025, the 1st U.S. Circuit Court of Appeals upheld the federal ban on marijuana, rejecting a legal challenge by several Massachusetts cannabis businesses. This decision underscores the ongoing tension between federal law and evolving state cannabis regulations. Additionally, while the Biden administration has proposed reclassifying marijuana to a less restricted category, the outcome remains uncertain, especially under a new administration.

June 2025 Watchlist: Best Canadian Cannabis Stocks for Growth

See News Rankings

Charts implemented using Lightweight Charts™